Research · Aug 25, 2026
Cardiac Cell Therapy Receives First Reimbursed Price in Japan
Japan's conditional approval pathway set a ¥53.2 million reimbursed price for ReHeart, making MHLW the first regulator to price cardiac cell therapy.
グロース · 医薬品 · 医薬品 · JP
Research · Aug 25, 2026
Japan's conditional approval pathway set a ¥53.2 million reimbursed price for ReHeart, making MHLW the first regulator to price cardiac cell therapy.